FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The FDA has placed a clinical hold on Ocugen Inc OCGN Phase 2/3 immuno-bridging and broadening study for COVAXIN (BBV152) OCU-002. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!